Your shopping cart is currently empty

Ledipasvir D-tartrate (GS-5885 D-tartrate) is an HCV NS5A inhibitor that suppresses viral overphosphorylation and replication, and is used for the treatment of hepatitis C virus.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $30 | - | In Stock | |
| 5 mg | $68 | - | In Stock | |
| 10 mg | $88 | - | In Stock | |
| 25 mg | $157 | - | In Stock | |
| 50 mg | $247 | - | In Stock | |
| 100 mg | $446 | - | In Stock | |
| 200 mg | $749 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $100 | - | In Stock |
| Description | Ledipasvir D-tartrate (GS-5885 D-tartrate) is an HCV NS5A inhibitor that suppresses viral overphosphorylation and replication, and is used for the treatment of hepatitis C virus. |
| Targets&IC50 | GT1b:4 pM, GT1a:34 pM (EC50) |
| In vitro | Method: Ledipasvir D-tartrate antiviral activity against HCV genotypes 1a and 1b and protein-adjusted EC50 values were determined using replicon systems. Protein binding and inhibitory effects on the JFH/3a-NS5A replicon were also evaluated. Result: Ledipasvir D-tartrate exhibited EC50 values of 31 pM and 4 pM against genotypes 1a and 1b, respectively, with protein-adjusted EC50 values of 210 pM and 27 pM. It showed high protein binding. The EC50 against the JFH/3a-NS5A replicon was 141 nM. [2] |
| In vivo | Method: Pharmacokinetic parameters of Ledipasvir D-tartrate, including plasma half-life, systemic clearance (CL), and steady-state volume of distribution (Vss), were measured in rats and dogs to evaluate its in vivo pharmacokinetic properties. Result: Ledipasvir D-tartrate exhibited favorable plasma half-lives in rats (1.83 ± 0.22 hours) and dogs (2.63 ± 0.18 hours), low systemic clearance, and moderate Vss values greater than total body water volume. The drug demonstrated good bioavailability and long half-lives in various primates, with predicted low clearance in humans. [1] |
| Synonyms | GS-5885 D-tartrate |
| Molecular Weight | 1039.09 |
| Formula | C53H60F2N8O12 |
| Cas No. | 1502654-87-6 |
| Smiles | [C@H]([C@@H](C(O)=O)O)(C(O)=O)O.C([C@@H](NC(OC)=O)[C@@H](C)C)(=O)N1CC2(C[C@H]1C=3NC(=CN3)C=4C=C5C(=CC4)C=6C(C5(F)F)=CC(=CC6)C=7C=C8C(=CC7)N=C(N8)[C@H]9N(C([C@@H](NC(OC)=O)C(C)C)=O)[C@]%10(C[C@@]9(CC%10)[H])[H])CC2 |
| Relative Density. | no data available |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||
| Solubility Information | DMSO: 20 mg/mL (19.25 mM), Sonication is recommended. | ||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (1.92 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
| |||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.